2162 results about "Peripheral blood" patented technology

The invention discloses a diagnostic marker of an acute myelogenous leukemia prognosis model as well as application and a prediction method of the diagnostic marker, and relates to the field of acute myelogenous leukemia prognosis research. The prognosis model is a prognosis model of acute myelogenous leukemia based on eight clinical characteristics, namely the disease age, the LDH level during disease, the RUNX1 gene, the KMT2A gene, the TP53 gene, the DMNT3A gene, the CBFB:: MYH11 gene and whether the first course of treatment is relieved or not; the construction method comprises the following steps of: sequentially carrying out univariate Cox regression analysis, Kaplan-Meier survival analysis and multivariate Cox regression analysis on clinical data of a patient from a data set and RNA sequencing data of peripheral blood and bone marrow samples in combination with survival information, further weighting an expression level according to an obtained regression coefficient, and carrying out quantitative analysis on the expression level. And establishing a prognosis model of acute myelogenous leukemia based on eight clinical characteristics. The acute myelogenous leukemia prognosis model disclosed by the invention has a relatively good evaluation effect.

The invention discloses a combination of different nucleic acid aptamers with known 291 targets, sequences of the nucleic acid aptamers of the combination are subjected to sequencing analysis through a single-cell high-throughput sequencing technology, and a cell map aiming at peripheral blood-derived mononuclear cells of a biliary tract cancer patient can be constructed. The nucleic acid aptamers covered by the combination have high specific affinity to molecular targets of the nucleic acid aptamers, and after the two ends of the nucleic acid aptamer sequences extend to adapt to joints of a commercial sequencing platform, high-throughput sequencing is carried out on the nucleic acid aptamer sequences which are combined with the surfaces of mononuclear cells and are provided with the sequencing joints; high-throughput analysis of the biomarkers on the surface of the peripheral blood-derived mononuclear cell of a biliary tract cancer patient can be realized, so that the cell map of the peripheral blood-derived mononuclear cell of the biliary tract cancer is constructed.

The invention belongs to the field of molecular biology and immunology, and particularly relates to an anti-CD3 nano antibody capable of activating the activity of T cells as well as a preparation method and application of the anti-CD3 nano antibody. The invention provides a preparation method of the anti-CD3 nano antibody. The preparation method comprises the following steps: constructing a CD3 plasmid and an overexpression cell line, and immunizing alpaca to obtain peripheral blood mononuclear cells (PBMC) of the alpaca; extracting RNA (Ribonucleic Acid) and carrying out reverse transcription to obtain cDNA; carrying out PCR amplification on the antibody gene segment and cloning the antibody gene segment to a phage display vector; and electrically transforming the vector into SS320 competent cells to obtain the nano antibody library. After two rounds of panning, detecting and screening an antibody clone capable of being combined with the CD3 protein through ELISA (Enzyme-Linked Immunosorbent Assay); an antibody sequence is selected through sequencing, and an antibody protein is expressed by using a mammalian cell high-throughput expression system; and then detecting and screening the antibody which is only specifically combined with the CD3. The method disclosed by the invention is simple, convenient and rapid to operate, and can be used for preparing active antibodies for treating potential tumors and proliferative diseases.

The invention provides a human body biological age detection method based on DNA methylation, which comprises the following steps: step S1, aiming at at least one subject, collecting a peripheral blood sample of the subject, and extracting DNA in blood from the sample; the method comprises the following steps: S1, extracting DNA, S2, measuring a methylation map of the extracted DNA to obtain detailed information of the methylation state of the DNA, and S3, calculating a corresponding methylation rate according to the strength of a methylation signal and a non-methylation signal in the obtained methylation map; and step S4, inputting the calculated DNA methylation rate into a biological age model obtained by pre-training to obtain the biological age corresponding to the subject. The method has the beneficial effects that the biological age can be accurately predicted by acquiring methylation information of DNA data, a novel biomarker-based assessment means is provided, and the method has important application value in health management, disease risk assessment and the like.

The invention discloses a patient immune response monitoring method and system for cell drug clinical research, and the method comprises the following steps: 1, obtaining a peripheral blood sample of a patient, and preprocessing the peripheral blood sample to obtain patient sample components; multi-dimensional immune indexes and cell drug specific immune response are detected by comprehensively utilizing multiple technologies, immune cell subsets, cell factors, immune globulin, T cell response and the like are covered, and therefore a complex immune response system is comprehensively reflected; peripheral blood samples are collected at multiple time points according to a cell drug action mechanism and a half-life period, and the whole-course change of the immunoreaction is effectively tracked, so that the development trend of the immunoreaction is accurately grasped; the method has the advantages that the characteristics are visually presented by constructing the immune response atlas of the patient, evaluation and prediction are assisted, real-time monitoring reports and treatment suggestions are provided according to evaluation and prediction results, doctors are assisted to adjust treatment in time, and accordingly the safety and effectiveness of cell drug treatment are improved.

The invention relates to the technical field of biological medicines, and particularly discloses an anti-human CD3 rabbit recombinant monoclonal antibody as well as a preparation method and application thereof. The antibody obtains anti-CD3 immune response by immunizing a rabbit, is obtained by combining single B cell sorting, gene cloning and a mammalian cell expression system, and has high affinity and good specificity. The antibody can effectively recognize CD3 positive T cells in human peripheral blood and can be applied to the fields of flow cytometry, immunohistochemistry, T cell function research and the like. Experimental results show that the antibody has the advantages of high titer, strong fluorescence signal, low background and the like, and is superior to the traditional murine anti-CD3 antibody. Amino acid sequences of light chain and heavy chain variable regions of the antibody are further obtained, and controllability and repeatability of antibody expression are achieved. The antibody has important scientific research value and industrial application prospect, and is suitable for various scenes such as T cell marker detection, immune state evaluation, immunotherapy auxiliary research and the like.

The invention discloses a detection method of a systemic lupus erythematosus immune spectrum based on full spectrum flow cytometry, and relates to the technical field of cell detection, and the detection method comprises the following steps: providing a fluorescein coupling antibody of a detection index; carrying out antibody titration on the fluorescein coupling antibody to obtain a dyeing concentration; the method comprises the following steps: carrying out surface staining on peripheral blood mononuclear cells of an SLE patient by adopting a fluorescein coupled antibody, carrying out intracellular mitochondrial superoxide staining, and resuspending in a detection solution to obtain a test sample; carrying out sample loading test on the test sample and the prepared single staining reference sample and negative sample, and collecting and analyzing particle information; and performing enclosure and dimension reduction analysis on the analyzed data to obtain a systemic lupus erythematosus immune spectrum and a cell activation state analysis result. According to the application, dozens of immune cell subtypes and activation states thereof in SLE can be detected under the condition of a single-tube sample, an SLE patient immune map is constructed, and a reference is provided for evaluating disease progression and formulating a treatment scheme.

The invention provides a tumor detection data analysis method based on a peripheral blood immune marker, and belongs to the technical field of immunodetection.The tumor detection data analysis method comprises the steps that firstly, a peripheral blood sample of a patient is collected, and plasma and cell components are separated; analyzing various immune cell phenotypes by using flow cytometry; determining the concentration of key cell factors; analyzing the molecular expression level of the immune checkpoint; establishing an immune cell subset proportion empirical function; analyzing a cell factor expression mode by using an immune lineage transcriptome analysis model; establishing a tumor immune microenvironment score by combining the immune cell subset proportion and a model output result; the accuracy of the scoring system is verified through clinical follow-up visit and iconography examination; a standardized report template is formulated to provide a tumor early detection basis. Wherein the immune lineage transcriptome analytical model adopts a multi-modal attention fusion network architecture, three different immune data streams can be processed and integrated at the same time, and accurate evaluation of tumor-related immune states is realized.

The present invention relates to: a method for evaluating the efficacy of an anti-cancer drug, a method for screening an anti-cancer drug, a system for evaluating the efficacy of an anti-cancer drug, or a system for screening an anti-cancer drug, using a mixture of peripheral blood mononuclear cells (PBMC) and a cancer organoid. Specifically, the present invention relates to: a method for evaluating the efficacy of an anti-cancer drug, a method for screening an anti-cancer drug, a system for evaluating the efficacy of an anti-cancer drug, or a system for screening an anti-cancer drug, using a mixture of cytotoxic T cells differentiated from PBMC and cancer organoids. According to the method for evaluating the efficacy of an anti-cancer drug, the screening method, the efficacy evaluation system, or the screening system of the present invention, a tumor microenvironment, i.e. The form in which cancer cells are present in a living body, can be very closely reproduced. Furthermore, since PBMCs derived from normal individuals are used and differentiated into cancer patient-specific cytotoxic T cells, the burden of collecting biological samples such as blood and tissue samples from cancer patients can be reduced, and the efficacy of an anti-cancer drug can be evaluated with high accuracy.

The invention discloses a test strip for five-item combined detection of inflammation of peripheral blood as well as a preparation method and application of the test strip. The test strip comprises a PVC bottom plate, a nitrocellulose membrane, a glass cellulose membrane combination pad, a sample pad and a water absorption pad, the PVC bottom plate is located at the bottommost part, and the sample pad, the glass cellulose membrane combination pad, the nitrocellulose membrane and the water absorption pad are sequentially arranged above the PVC bottom plate; the nitrocellulose membrane is provided with an HBP, PCT, IL-6, CRP and SAA detection line and a mouse anti-DNP monoclonal antibody quality control line; the glass nitrocellulose membrane combination pad is provided with a combination of a fluorescent microsphere-labeled HBP antibody, a fluorescent microsphere-labeled PCT antibody, a fluorescent microsphere-labeled IL-6 antibody, a fluorescent microsphere-labeled CRP antibody, a fluorescent microsphere-labeled SAA antibody and a fluorescent microsphere-labeled DNP-BSA. According to the test strip, fluorescence immunochromatography is carried out by utilizing the principle of a double-antibody sandwich method in combination with the characteristics of fluorescent microspheres, and rapid, specific, simple, convenient and sensitive joint detection on HBP, PCT, IL-6, CRP and SAA is realized at the same time.

The invention provides an in-vitro culture method of T cells, and belongs to the technical field of genetic engineering.The culture method comprises the steps that immune cell serum-free culture media are added into peripheral blood mononuclear cells, and activated culture is conducted in the presence of cell factors to obtain activated T cells; the cell factor comprises an IL-2 monoclonal antibody and a CD3 monoclonal antibody, and further comprises two or three of an iCAM1 protein, a CCL21 protein and OK432. The T cells obtained through activation and multiplication culture are relatively stable in cell phenotype, relatively large in amplification multiple, relatively high in cell viability and relatively high in tumor killing efficiency. T cells are obtained after activation is performed for 24 hours and then multiplication culture is performed for 14 days, and the number of the cells is 6.2-8.9 * 10 < 9 >; the killing rate on Hela cells is 51.9 to 74.1 percent, and the killing rate on LOVO cells is 55.7 to 80.5 percent.

The invention relates to lauroyl cilostazol as well as a preparation method and application thereof. Wherein the lauroyl cilostazol is sterile, and preferably, the lauroyl cilostazol is a crystal. The invention further provides application of the lauroyl cilostazol in preparing medicines for treating cerebral infarction, cerebrovascular diseases, atherosclerosis, diabetic complications, peripheral vascular diseases, Reynolds diseases, intermittent claudication, ischemic heart diseases and acute coronary syndromes. The lauroyl cilostazol has the remarkable long-acting characteristic.

The invention provides a bispecific antibody targeting CD3 and MICA and an application of the bispecific antibody. The present invention relates to a conjugate comprising: a first antigen binding region comprising an anti-CD3 antibody or an antigen binding fragment thereof; the present invention relates to an anti-CD3 antibody or an antigen-binding fragment thereof, comprising a first antigen-binding region having MICA binding activity, a second antigen-binding region having MICA binding activity, the anti-CD3 antibody or the antigen-binding fragment thereof comprising a first heavy chain variable region having a specific CDRs amino acid sequence and a first light chain variable region. The bispecific antibody disclosed by the invention can be combined with CD3 and MICA so as to promote T cell activation, secrete cell factors and effectively promote PBMC (peripheral blood mononuclear cells) to kill tumor cells, so that the bispecific antibody has good anti-cancer activity; moreover, the bispecific antibody has reduced proinflammatory cytokine secretion promotion performance and T cell activation promotion performance, is higher in safety, and has good clinical application value and drug development value.

The invention provides a construction method of an anti-programmed death protein-1 monoclonal antibody treatment response prediction model, and belongs to the technical field of construction methods of prediction models. The method comprises the following steps: acquiring a blood sample of a non-small cell lung cancer patient; extracting peripheral blood mononuclear cells of the blood sample of the patient before and after the treatment of the anti-programmed death protein-1 monoclonal antibody; sequentially carrying out treatment through the steps of protein extraction, reductive alkylation and enzymolysis to obtain a sample peptide fragment; performing basic characteristic analysis and function annotation to obtain a protein spectrum and a modification spectrum of peripheral blood mononuclear cells of the non-small cell lung cancer patient treated by the anti-programmed death protein-1 monoclonal antibody; screening by utilizing machine learning to obtain a biomarker; and monitoring to obtain the anti-programmed death protein-1 monoclonal antibody treatment response prediction model. The method can be used for predicting the treatment effect of the anti-programmed death protein-1 monoclonal antibody of a non-small cell lung cancer patient.

The present invention discloses a combination of different nucleic acid aptamers with 291 known targets. By performing sequencing analysis on the nucleic acid aptamer sequences of this combination through single-cell high-throughput sequencing technology, a cell atlas targeting mononuclear cells derived from the peripheral blood of patients with cholangiocarcinoma can be constructed. The nucleic acid aptamers covered by this combination have high specific affinity for their molecular targets. After extending adapters commercialized for sequencing platforms at both ends of the nucleic acid aptamer sequences respectively, by performing high-throughput sequencing on the nucleic acid aptamer sequences with sequencing adapters bound to the surface of mononuclear cells, high-throughput analysis of biomarkers on the surface of mononuclear cells derived from the peripheral blood of patients with cholangiocarcinoma can be achieved, thereby constructing a cell atlas of mononuclear cells derived from the peripheral blood of cholangiocarcinoma.

Embodiments of the invention include compositions and methods related to engineered human mucosal-associated invariant T (eMAIT) cells for off-the-shelf use for clinical therapy for cancer, infectious, and autoimmune diseases. In some embodiments, the eMAIT cells are produced from healthy human donor peripheral blood, cord blood, or G-CSF mobilized peripheral blood. In particular embodiments, the eMAIT cells are produced from a pluripotent stem cell line and therefore can be of unlimited supply. In some embodiments, the eMAIT cells are engineered to express chimeric antigen receptors (CARs), or / and immune regulatory molecules, or / and allorejection resistance molecules. Embodiments of the invention also include compositions of matter comprising polynucleotides encoding mucosal-associated invariant T cell receptor alpha chain polypeptides and / or mucosal-associated invariant T cell receptor beta chain polypeptides.

The invention discloses application of a gene marker in early screening of esophagus, stomach and intestine multiple cancer species, an early screening model construction method and a detection device, and belongs to the technical field of early noninvasive detection of digestive tract tumors. By analyzing the whole genome characteristics of circulating free DNA in peripheral blood, a novel multi-cancer-species screening system is established. On the basis of low-depth whole genome sequencing data, molecular markers in three dimensions, namely a genome copy number variation mode, a DNA fragment distribution characteristic with a specific length and an epigenetics signal of a transcription initiation region, are emphatically detected. An advanced converter neural network architecture is adopted, and the model can efficiently capture complex feature association in a whole genome range through a specific self-attention mechanism. The model design particularly considers the particularity of genome data, introduces an adaptive position coding system, and accurately reflects the spatial distribution relationship of DNA fragments on chromosomes. Therefore, the system can still maintain excellent detection performance under extremely low sequencing depth.

The invention relates to the field of noninvasive prenatal diagnosis, and particularly discloses a preeclampsia noninvasive screening method based on deep sequencing 8bp oligonucleotide double-fragment characteristics, which comprises the following steps: collecting preeclampsia and healthy pregnant woman peripheral blood samples, and extracting free DNA for high-throughput sequencing; the method comprises the following steps: extracting core 8-mer sequences' GTGCGCCC 'and' GATGGGGT 'in a long fragment of 150-200bp through bioinformatics analysis; an integrated support vector machine, K-nearest neighbor, extreme gradient lifting, a random forest and a multi-layer perceptron are combined with a logistic regression element classifier to construct a stacking model, the frequency of a core sequence is normalized, machine learning analysis is carried out, and the preeclampsia risk is predicted. According to the invention, two 8bp oligonucleotide characteristic fragments are specifically screened, and a deep learning architecture of multi-model fusion is combined, so that the limitations of low specificity and invasive detection of a traditional screening method are effectively broken through.

Systems and methods can facilitate wide broad-band IVUS for peripheral vascular applications with simultaneous improved resolution and penetration depth. A custom analog front end interface can withstand large voltages and recover to receive a sub-mV pulse from less than one mm away. The custom analog front end interface can be on an interface chip that can be sized to be integrated within a tip of the IVUS catheter to connect micro-cables within the IVUS catheter to the broad-band transducer. The interface chip can also include a dual-stage amplifier having a pulse mode configured to withstand voltage pulses greater than 30 VPP during pulsing and an echo reception mode configured to receive sub-mV echoes during echo reception.

The invention discloses a computer device and a computer readable storage medium for evaluating the immune reconstitution state of an HIV infected person after ART. Belongs to the field of computer information. The technical problem to be solved by the invention is how to evaluate the immune reconstruction state of an HIV infected person after ART. The invention provides a computer program stored in a memory in a computer device. The computer program comprises the following steps: S1, receiving sample data, namely the proportion of the number of cells expressing PD-1 in CD8 + T cells of peripheral blood mononuclear cells of an HIV infected subject after ART and the proportion of the number of cells expressing at least one of the following five factors: CD38, HLA-DR, CD57, PERFORIN and CD107A; s2, obtaining a predicted value Y from the sample data through a model formula, and outputting an immune reconstruction condition according to the predicted value Y and a pre-judgment condition; the method can accurately and efficiently determine whether the immune reconstruction state of the HIV infected person subjected to antiviral treatment is good or not.

The invention relates to the technical field of tumor neoantigen detection, and particularly discloses a neoantigen prediction method and system for a malignant solid tumor, and the method comprises the following steps: obtaining a tumor sample and a peripheral blood sample, and carrying out DNA and RNA sequencing; analyzing and processing to obtain DNA (Deoxyribonucleic Acid) sequencing data and RNA (Ribonucleic Acid) sequencing data; analyzing to obtain an HLA typing result and a sequence of the mutant protein; calculating to obtain related characteristic values of the new antigens; calculating a new antigen score; and intercepting the first N pieces with the highest scores to obtain a neoantigen prediction result of the malignant solid tumor. Starting from the action mechanism of the new antigens, according to key steps of the prediction process, a plurality of characteristic values are selected, a hard filtering index is not adopted, a product mode is adopted, and the score of the new antigens is calculated according to the score of the relevant characteristic values of the new antigens.

The invention provides a non-invasive blood pressure estimation method, device and equipment, a storage medium and a product, and belongs to the technical field of biomedicine, and the method comprises the steps that an ECG signal and an ICG signal are preprocessed; generating physiological feature indexes, wherein the physiological feature indexes comprise conventional indexes and special indexes; determining an incidence relation between the conventional index and the basic peripheral vascular resistance parameter as well as the basic artery compliance parameter; inputting the conventional indexes into a pre-trained machine learning model, and outputting basic peripheral vascular resistance prediction parameters and basic artery compliance prediction parameters; performing dynamic correction according to the special indexes, and generating a target peripheral vascular resistance parameter and a target artery compliance parameter; and calculating and generating a blood pressure estimation result. According to the non-invasive blood pressure estimation method, device and equipment, the storage medium and the product, the accuracy, dynamic nature and stability of non-invasive blood pressure estimation can be improved.

The invention discloses a pharmaceutical composition for promoting aTreg cell differentiation and application thereof, and relates to the field of biological medicine, and the pharmaceutical composition comprises zinc salt, a basic cell culture medium, fetal calf serum, antibiotic, L-glutamine and a pH buffer agent. According to the application, the basic cell culture medium is used for providing basic nutrition required by cell growth for lymphocytes, the fetal calf serum is used for providing growth factors, hormones, adhesion proteins and nutrient substances required by cell growth for the lymphocytes, and the antibiotics are used for preventing bacterial infection; l-glutamine provides key amino acid for cell energy metabolism and participates in synthesis of protein and nucleic acid, zinc salt provides zinc ions, and under the comprehensive action, the proportion of Treg cells and aTreg cells differentiated from lymphocytes in peripheral blood mononuclear cells is increased.

The invention discloses a reagent for rapidly distinguishing bacterial and virus infection and application, belongs to the field of molecular biology, relates to medical and biotechnology, and aims to solve the problem that a traditional method cannot clearly distinguish bacterial infection from virus infection. The reagent comprises five antibodies marked with different fluorescence. The five antibodies are all mouse anti-human or rabbit anti-human antibodies, and targets corresponding to the five antibodies are respectively CD45, CD14, CD64, CD169 and HLA-DR (human leukocyte antigen-DR). The tail end of the antibody is connected with different fluorescein through chemical reaction; fluorescence labeling is performed on neutrophils, mononuclear cells and lymphocytes in peripheral blood through an antibody combination of CD molecules, and corresponding infection indexes are calculated through a flow cytometry method, so that the infection type (bacterial / virus infection) of a patient is quickly distinguished and judged.

The invention relates to application of 4-GBA in preparation of a medicine for improving infection endurance capacity of a sepsis patient, 4-GBA is used for treating mice infected with sepsis, compared with control mice, the survival rate of the mice treated by the 4-GBA is far larger than that of the control mice, and experiments prove that the 4-GBA has a protection effect on sepsis infection. The mechanism of 4-GBA for improving infection endurance capacity of sepsis patients is researched, and after 4-GBA treatment, the content of liver and kidney functional markers in peripheral blood serum of mice infected with sepsis is remarkably reduced, the content of DAMPs (injury related molecular patterns) related molecules in peripheral blood serum of mice infected with sepsis is remarkably reduced, and the application of 4-GBA in the treatment of the mice infected with sepsis in the treatment of the infection endurance capacity of the patients infected with sepsis in the treatment of the infection endurance capacity of the patients infected with sepsis in the treatment of the patients infected with sepsis in the treatment of the patients infected with sepsis. And the product does not have in-vivo and in-vitro sterilization functions and body immune regulation functions. The result shows that 4-GBA can improve the infection endurance capacity of the sepsis patient, and provides a new direction and a new drug for treatment of the sepsis patient.

The invention provides an anti-human BCMA monoclonal antibody and a hybridoma cell strain, the antibody has strong affinity with a BCMA antigen, the Kd value is 1.892 * 10 <-8 > M, and the antibody can compete with a commodity BCMA antibody 19F2 to combine with a target cell; the antibody can be specifically combined with a BCMA positive cell line H929, and has no cross reaction with a BCMA negative cell line Raji and peripheral blood source T cells; the monoclonal antibody 2D2 not only can be used for detecting cells expressing human BCMA, but also can be applied to tumor immunotherapy of targeted human BCMA, and has diagnosis and treatment values.

The invention relates to the technical field of biology, in particular to a Treg cell amplification culture medium and a preparation method of Treg cells. According to the method for in-vitro amplification of the regulatory T cells (Treg) from peripheral blood, the amplification efficiency and purity of the Treg cells are improved, the culture cost is reduced, the culture period is shortened, and the problem of trophoblast cell residues in subsequent clinical application is solved.

The invention discloses construction and application of a targeted exosome chimeric antigen receptor molecule for treating HIV (human immunodeficiency virus) infection, and belongs to the technical field of biological medicines. According to the invention, the mRNA for coding the anti-HIV CAR is directionally packaged into the targeting exosome. Nanometer antibody sequences of CD3, CD4 and CD8 < + > T receptors on targeted T cells are fused to the N terminal of LAMP-2B to construct a specific targeting plasmid, so that targeting peptides are expressed on the surface of an exosome membrane, expression plasmids containing RNA binding protein L7A and exosome tag protein CD63 are constructed, and HEK293F cells are co-transfected by the expression plasmids and CAR plasmids containing C / D box to obtain the exosome loaded with CAR mRNA and targeted to the T cells. When the exosome is incubated with PBMC (peripheral blood mononuclear cells) in vitro or is transfused back into a humanized mouse body, human CAR-T cells can be constructed, and the exosome has remarkable activity of killing virus infected cells.

Disclosed are methods for producing a population of autologous engineered cells to be reinfused into a subject comprising extracorporeally transfecting an internal payload into a population of target cells from a sample obtained from the subject by incubating the population of cells with a lipid nanoparticle (LNP) and / or targeting lipid nanoparticle (tLNP) in an incubation component of an extracorporeal system for no more than 6 hours.

The invention provides an applicable population screening method and application of a glioma dry-like cell sensitized DC vaccine, peripheral blood of a patient before and after inoculation of the glioma dry-like cell sensitized DC vaccine is obtained, mononuclear cells are extracted, CD8 + T cells are respectively separated from the mononuclear cells through a magnetic bead sorting method, and the CD8 + T cells are separated from the mononuclear cells. The method comprises the following steps: uniformly inoculating CD8 < + > T cells into an ELISPOT cell culture plate coated with an IFN-gamma antibody for culture, respectively setting an experimental group and a positive control group for culture, adding A2B5 < + > glioma cell lysis buffer into the experimental group and adding phytohemagglutinin into the positive control group, and carrying out ELISPOT staining on the cultured cells to obtain the secretion amount of FN-gamma before and after treatment of a patient. According to the secretion amount of the FN-gamma, patients with specific immune response to the glioma dry-like cell sensitization DC vaccine are screened, so that the glioma dry-like cell sensitization DC vaccine is conveniently popularized and applied, and the immune mechanism of the glioma dry-like cell sensitization DC vaccine is researched.